Corporate Member Update- Takeda- EXKIVITY™ (mobocertinib)

New Targeted Therapy for EGFR Exon 20 Insertion-Positive mNSCLC

Takeda Oncology is pleased to announce that the US Food and Drug Administration (FDA) has approved EXKIVITY™ (mobocertinib), the first oral therapy to target epidermal growth factor
receptor (EGFR) exon 20 insertion mutations in metastatic non-small cell lung cancer (NSCLC).

To read the full press release, please click here.